Herbalife is a high-leverage recovery story: modest sales stabilization, aggressive deleveraging, and personalized nutrition create substantial upside despite GLP-1, regulatory, and leadership risks.
Overview
Herbalife Ltd. is a global consumer health and wellness company selling supplements, meal replacements, sports nutrition, and personal-care products through an independent-distributor MLM model in more than 90 markets. Its localized Nutrition Clubs and coaching network differentiate the company from conventional retail, while Weight Management remains the largest category at approximately 58% of sales. The investment case is transitioning from historical contraction toward stabilization: Q2 FY2026 net sales increased 5.4% reported and 5.8% in constant currency to $1,326.8M, marking the fourth consecutive quarter of top-line growth. India and Latin America grew 15.2% and 16.6%, respectively, while China fell 24.5%. **Valuation is deeply discounted at 0.24x sales, 7.7x trailing P/E, and approximately 4.0x EV/adjusted EBITDA.** Adjusted EBITDA was $166.6M, or a 12.6% margin, and first-half operating cash flow rose 52% to $146.7M, although adjusted EPS of $0.51 missed consensus by approximately 19.1%. **Near-term catalysts are deleveraging toward $1.4B by 2028, the $250M buyback, and personalized nutrition/Bioniq and GLP-1 initiatives.** The principal counterweights are $2.0B of debt, leadership transitions, GLP-1 competition, and regional weakness.